Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

Authors
Category Systematic review
ConferenceMenopause
Year 2023
This article has no abstract
Epistemonikos ID: b3c5180be6fa287905b68de5195064d01f815027
First added on: Apr 30, 2026